Progress: Procedure completed
| Role | Committee | Rapporteur | Shadows |
|---|---|---|---|
| Lead | CONT |
GERBRANDY Gerben-Jan ( ALDE)
|
SARVAMAA Petri ( PPE),
AYALA SENDER Inés ( S&D),
STAES Bart ( Verts/ALE),
BRADBOURN Philip ( ECR),
ANDREASEN Marta ( EFD),
EHRENHAUSER Martin ( NA)
|
| Committee Opinion | ENVI |
HAUG Jutta ( S&D)
|
Lead committee dossier:
Subjects
Events
PURPOSE: to grant discharge to the European Medicines Agency (EMA) for the financial year 2011.
NON-LEGISLATIVE ACT: Decision 2013/584/EU of the European Parliament on discharge in respect of the implementation of the budget of the European Medicines Agency for the financial year 2011.
CONTENT: with this Decision and in accordance with Article 319 of the Treaty on the Functioning of the European Union (TFEU), the European Parliament gives discharge to the Executive Director of the European Medicines Agency for the implementation of the Agency’s budget for 2011.
The Decision is consistent with the European Parliament’s resolution adopted on 17 April 2013 and includes a series of observations that form an integral part of the discharge decision (refer to the summary of the opinion of 17 April 2013).
Decision 2013/585/EU, adopted on the same day, approves the closure of the accounts for this Community agency for 2011.
The European Parliament adopted a decision on discharge to be granted to the Executive Director of the European Medicines Agency (EMA) in respect of the implementation of the Agency's budget for the financial year 2011. The vote on the decision to grant discharge covers the closure of the accounts (in accordance with Annex VI, Article 5(1) of the European Parliament’s Rules of Procedure).
Noting that the Court of Auditors stated that it has obtained reasonable assurances that the annual accounts of the Agency for the financial year 2011 are reliable and that the underlying transactions are legal and regular, Parliament adopted a resolution containing a number of recommendations that need to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies :
Financing, budget and financial management : Parliament recalls that the Agency's budget for 2011 was EUR 208 863 000, which represents a nominal increase over the financial year 2010. It recalls that the total Union contributions amounted to EUR 39 765 191.39 for 2011, which represents an 8.65% increase compared to the previous year and that the rest was financed by fees paid by the pharmaceutical industry when applying for, obtaining or maintaining Union marketing authorisations. Members state that a large amount of the Agency's revenue is estimated to have derived from the fee revenue, which continues to increase year on year. Members are concerned as regards the need to introduce a system of remuneration for services provided by Member States’ authorities, based on their real costs. Implementation rate of appropriations : Parliament observes that in terms of committed and paid appropriations, the Agency's execution rate stands at 95.21% and 81.97% respectively. It calls on the Agency to continue its efforts to improve its execution rate of payment. It is concerned that once again, the Court of Auditors reported that payment appropriations for Title II ("Administrative expenditure") have been carried over to 2012, representing 29% of the budget which is excessive and at odds with the principle of annuality. Recruitment procedures : Parliament states the lack of transparency in the staff selection procedures. It states that there was no evidence of any action taken to address the issues. Conflicts of interest : noting the problems as regards the conflict of interest in the light of the previous discharge procedure, Parliament welcomes the efforts made but state that the Agency did not adequately manage conflict of interest situations. It welcomes the Agency's commitment to undertake in the first half of 2013 a review of the implementation of its revised policy on the handling of conflicts of interests and that an ex ante and ex post check on the handling of conflicts of interests is currently being developed for implementation in the second quarter of 2013. The Agency is called upon to keep the discharge authority informed on their respective outcomes.
Lastly, Parliament made a series of observations concerning the procurement procedures and controls carried out by this Community Agency.
The Committee on Budgetary Control adopted the report by Gerben-Jan GERBRANDY (ADLE, NL) on discharge to be granted to the Executive Director of the European Medicines Agency (EMA) in respect of the implementation of the Agency's budget for the financial year 2011.
Noting that the Court of Auditors stated that it has obtained reasonable assurances that the annual accounts of the Agency for the financial year 2011 are reliable and that the underlying transactions are legal and regular, Members approve the closure of the Agency’s accounts. However, they make a number of recommendations that need to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies :
Financing, budget and financial management : Members recall that the Agency's budget for 2011 was EUR 208 863 000, which represents a nominal increase over the financial year 2010. They recall that the total Union contributions amounted to EUR 39 765 191.39 for 2011, which represents an 8.65% increase compared to the previous year and that the rest was financed by fees paid by the pharmaceutical industry when applying for, obtaining or maintaining Union marketing authorisations. Members state that a large amount of the Agency's revenue is estimated to have derived from the fee revenue, which continues to increase year on year. Members are concerned as regards the need to introduce a system of remuneration for services provided by Member States’ authorities, based on their real costs. Implementation rate of appropriations : Members observe that in terms of committed and paid appropriations, the Agency's execution rate stands at 95.21% and 81.97% respectively. They call on the Agency to continue its efforts to improve its execution rate of payment. They are concerned that once again, the Court of Auditors reported that payment appropriations for Title II ("Administrative expenditure") have been carried over to 2012, representing 29% of the budget which is excessive and at odds with the principle of annuality. Conflicts of interest : noting the problems as regards the conflict of interest in the light of the previous discharge procedure, Members welcome the efforts made but state that the Agency did not adequately manage conflict of interest situations. They welcome the Agency's commitment to undertake in the first half of 2013 a review of the implementation of its revised policy on the handling of conflicts of interests and that an ex ante and ex post check on the handling of conflicts of interests is currently being developed for implementation in the second quarter of 2013. The Agency is called upon to keep the discharge authority informed on their respective outcomes.
Lastly, Members made a series of observations concerning the recruitment and procurement procedures and controls carried out by this Community Agency.
Having examined the revenue and expenditure accounts for the financial year 2011 and the balance sheet at 31 December 2011 of the European Medicines Agency, as well as the Court of Auditors' report on the annual accounts of the Agency for the financial year 2011, accompanied by the Agency's replies to the Court's observations, the Council recommends the European Parliament to give a discharge to the Executive Director of the Agency in respect of the implementation of the budget for the financial year 2011.
The observations in the Court of Auditors' report in relation to the financial year 2011 call for some comments by the Council, which may be summarised as follows:
the Council welcomes the Court's opinion that, in all material respects, the Agency's annual accounts present fairly its financial position as at 31 December 2011 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of the Agency's Financial Regulation, and that the underlying transactions for that financial year are legal and regular; the Council, nevertheless, urges the Agency to improve its financial programming and its monitoring of the budget implementation in order to reduce the amounts carried over to the next financial year, in line with the budgetary principle of annuality; it notes the Court's findings in relation to the Agency's decision to increase the financial envelope of a framework contract where the Court had found irregularities, and which had given rise to the Court's qualified opinion in 2009. It notes that the Agency started preparing in 2011 a new framework contract. Moreover, the Council calls on the Agency to take actions to remedy the weaknesses found by the Court in the transparency of its procurement procedures ; the Council regrets the shortcomings detected by the Court in the transparency of the recruitment procedures, including the irregularities found regarding the conflict of interest declarations of the Selection Board members, and expects this to be fully remedied by the Agency.
PURPOSE: presentation of the EU Court of Auditors’ report on the annual accounts of the European Medicines Agency for the financial year 2011, together with the Agency’s reply.
CONTENT: in accordance with the tasks conferred on the Court of Auditors by the Treaty on the Functioning of the European Union, the Court presents to the European Parliament and to the Council, in the context of the discharge procedure, a Statement of Assurance as to the reliability of the annual accounts of each institution, body or agency of the EU, and the legality and regularity of the transactions underlying them, on the basis of an independent external audit.
This audit concerned, amongst others, the annual accounts of the European Medicines Agency (EMA).
In the Court’s opinion, the Agency’s Annual Accounts fairly present, in all material respects, its financial position as of 31 December 2011 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of its Financial Regulation.
The Court also considers that the transactions underlying the annual accounts of the Agency for the financial year ended 31 December 2011 are, in all material respects, legal and regular .
The report confirms that the Agency’s 2011 budget amounted to EUR 208.863 million and that the number of staff employed by the Agency at the end of the year was 728.
The report also makes a series of observations on the budgetary and financial management of the Agency, accompanied by the latter’s response. The main observations may be summarised as follows:
Court’s comments :
carry-overs: the Court notes again that the level of carry- over is excessive and at odds with the principle of annuality; public procurement: the Agency increased in 2011 the financial envelope of an irregular framework contract for IT services concluded in 2009 for which the Court had qualified its opinion on the legality and regularity of the transactions underlying the Agency’s 2009 accounts. According to the Court, there is scope for improving the transparency of procurement procedures as regards the justification of the estimated contract volumes and the definition, publication and application of selection criteria; recruitment: the Court identified a need to improve the transparency of staff selection procedures.
Agency’s replies :
the Agency states that since 2008 it has made every effort to reduce its level of carry-over to an acceptable level. It has in fact achieved a continuous reduction. As the operations of the Agency are of a multi-annual nature and not linked to the calendar year, a certain level of carry-overs is unavoidable; the Agency considers that the IT framework contract was not irregular. As a consequence, the extension of the framework contract is considered not irregular as well; the Agency has taken note of the Court’s comments and updated its procedures with a view to transparency and timely documentation.
Lastly, the Court of Auditors’ report contains a summary of the Agency’s activities in 2011 . This is focused on the following:
applications for marketing authorisations for 100 medicines for human use ; pharmacovigilance activities; mutual recognition procedures and decentralised procedures: started 6 401; (6 715 ended positively); scientific advice; applications for paediatric investigation plans: 187 relating to 220 indications; applications for marketing authorisations for 11 medicinal products for veterinary use; 449 inspections; herbal medicinal products; 166 applications for orphan medicinal products (111 favourable opinions); requests for SME status: 433 requests and 350 applications for fee reduction or deferrals.
PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2011, as part of the 2011 discharge procedure.
Analysis of the accounts of the European Medicines Agency (EMEA) .
CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2011 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA).
In 2011, the tasks and budget of this agency were as follows:
description of the Agency's tasks : the European Medicines Agency, which is located in London, was created by Council Regulation (EEC) No 2309/93 , which was replaced by Regulation (EC) No 726/2004 of the European Parliament and of the Council and its role is the coordination of the scientific resources made available by the national authorities in order to ensure the evaluation and supervision of medicinal products for human or veterinary use;
the Agency's budget for the 2011 financial year : the Agency’s budget for 2011, as presented in the Commission document on the consolidated annual accounts of the European Union , gives the following figures:
forecasted income budget: EUR 209 million; entitlements established : EUR 220 million; amounts received: EUR 199 million; outstanding : EUR 21 million.
forecasted income budget: EUR 209 million; entitlements established : EUR 220 million; amounts received: EUR 199 million; outstanding : EUR 21 million.
The complete version of the Agency's final accounts may be found at the following address: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500129887.pdf
PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2011, as part of the 2011 discharge procedure.
Analysis of the accounts of the European Medicines Agency (EMEA) .
CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2011 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA).
In 2011, the tasks and budget of this agency were as follows:
description of the Agency's tasks : the European Medicines Agency, which is located in London, was created by Council Regulation (EEC) No 2309/93 , which was replaced by Regulation (EC) No 726/2004 of the European Parliament and of the Council and its role is the coordination of the scientific resources made available by the national authorities in order to ensure the evaluation and supervision of medicinal products for human or veterinary use;
the Agency's budget for the 2011 financial year : the Agency’s budget for 2011, as presented in the Commission document on the consolidated annual accounts of the European Union , gives the following figures:
forecasted income budget: EUR 209 million; entitlements established : EUR 220 million; amounts received: EUR 199 million; outstanding : EUR 21 million.
forecasted income budget: EUR 209 million; entitlements established : EUR 220 million; amounts received: EUR 199 million; outstanding : EUR 21 million.
The complete version of the Agency's final accounts may be found at the following address: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500129887.pdf
Documents
- Final act published in Official Journal: Decision 2013/584
- Final act published in Official Journal: OJ L 308 16.11.2013, p. 0254
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament: T7-0150/2013
- Debate in Parliament: Debate in Parliament
- Committee report tabled for plenary: A7-0098/2013
- Amendments tabled in committee: PE497.879
- Document attached to the procedure: 05753/2013
- Committee opinion: PE500.745
- Committee draft report: PE497.831
- Court of Auditors: opinion, report: OJ C 388 15.12.2012, p. 0116
- Court of Auditors: opinion, report: N7-0022/2013
- Non-legislative basic document: COM(2012)0436
- Non-legislative basic document: EUR-Lex
- Non-legislative basic document published: COM(2012)0436
- Non-legislative basic document published: EUR-Lex
- Non-legislative basic document: COM(2012)0436 EUR-Lex
- Court of Auditors: opinion, report: OJ C 388 15.12.2012, p. 0116 N7-0022/2013
- Committee draft report: PE497.831
- Committee opinion: PE500.745
- Document attached to the procedure: 05753/2013
- Amendments tabled in committee: PE497.879
| Amendments | Dossier |
| 36 |
2012/2190(DEC)
2012/12/20
ENVI
11 amendments...
Amendment 1 #
Draft opinion Paragraph 1 a (new) 1a. Points to the role of the European Medicines Agency in protecting and promoting public and animal health by assessing and supervising medicines for human or veterinary use;
Amendment 10 #
Draft opinion Paragraph 8 a (new) 8a. Believes that the discharge decision for the Agency should be based upon OECD guidelines to ensure high-quality internationally recognised accounting, audit and financial disclosure standards; invites the European institutions to incorporate and commit to introducing OECD guidelines within a common working framework for all European institutions and bodies;
Amendment 11 #
Draft opinion Paragraph 8 b (new) 8b. Is of the opinion that the Agency should not be granted discharge in respect of the implementation of the Agency budget for the financial year 2011 until the general budget of the European Union is given an unqualified statement of assurance by the Court of Auditors.
Amendment 2 #
Draft opinion Paragraph 1 a (new) 1a. Draws attention to the Health and Consumer Protection Commissioner’s pledge to pursue an initiative for a common rulebook governing the auditing and management of the Agency and to tackle the various instances of conflicts for interest, whilst examining the scope for cuts to its operating budget;
Amendment 3 #
Draft opinion Paragraph 2 2. Thinks it is noteworthy in this context that the special report on Conflict of Interests by the Court of Auditors concluded that none of the agencies scrutinised, including the EMA, dealt properly with conflicts of interest; notes that the report is not taking into account to the full the latest developments and improvements put in place by the Agency; therefore, notes with satisfaction the improvement of all procedures related to transparency and possible conflicts of interest in the Agency; intends to ascertain that those procedures are in fact being implemented, especially as regards ex ante and ex post checks on declarations of interests, and will support the Executive Director in hi
Amendment 4 #
Draft opinion Paragraph 2 2. Thinks it is noteworthy in this context that the special report on Conflict of Interests by the Court of Auditors is not taking into account to the full the latest developments and improvements put in place by the Agency; therefore, notes with satisfaction the improvement of all procedures related to transparency and possible conflicts of interest in the Agency, recalls, however, the importance of continuously working for strengthening and enhancement of all policies related to transparency and independence and will support the Executive Director in hi
Amendment 5 #
Draft opinion Paragraph 2 2. Thinks it is noteworthy in this context that the special report on Conflict of Interests by the Court of Auditors is not taking into account to the full the latest developments and improvements put in place by the Agency; therefore, notes
Amendment 6 #
Draft opinion Paragraph 2 a (new) 2a. Looks to the Agency to produce a report on the implementation of the system of ex ante and ex post verification of declarations of interests; shares the view of the Agency’s Executive Director that, given its scope, a system of that kind is beyond the Agency’s capacity and remit; believes, therefore, that one option to consider should be a legislative initiative whereby holders of a marketing authorisation (MA) for a pharmaceutical product would be obliged to publish agreements and all benefits in cash or in kind that they provided, directly or indirectly, to experts or bodies with whom they worked;
Amendment 7 #
Draft opinion Paragraph 7 7. Acknowledges the efforts by the executive level of the Agency to encourage a decision by the Management Board to revise the system of remuneration of Member States services based on real costs;
Amendment 8 #
Draft opinion Paragraph 8 Amendment 9 #
Draft opinion Paragraph 8 8.
source: PE-502.119
2013/02/27
CONT
25 amendments...
Amendment 1 #
Proposal for a decision 1 Paragraph 1 1.
Amendment 10 #
Motion for a resolution Paragraph 4 a (new) 4a. Observes that in terms of committed and paid appropriations the Agency's execution rate stands respectively at 95.21% and 81.97% against 95.65% and 79.10% in 2010; calls on the Agency to continue its efforts to improve its execution rate of payment;
Amendment 11 #
Motion for a resolution Paragraph 5 5. Notes with concern that as in its
Amendment 12 #
Motion for a resolution Paragraph 7 7. Notes with concern the difference between the Court of Auditors' conclusion and the Agency's reply as regards the framework contract for IT services concluded in 2009, for which the Court had qualified its opinion on the legality and regularity of the transactions underlying the Agency's 2009 accounts; notes that the Court of Auditors considers the increase of the original contract ceiling to be irregular, while the Agency considers that the IT framework contract was not irregular, and therefore does not consider its extension as irregular either; urges the Agency to provide
Amendment 13 #
Motion for a resolution Paragraph 8 a (new) 8a. Notes that in 2011, the Agency advertised 15 vacancies for temporary agent positions and that at year-end the total number of staff at the Agency increased from 656 to 689; (To be placed under subtitle "recruitment procedures")
Amendment 14 #
Motion for a resolution Paragraph 9 9. Acknowledges from the Court of Auditors the need to improve the transparency of staff selection procedures;
Amendment 15 #
Motion for a resolution Paragraph 9 9. Acknowledges from the Court of Auditors the need to improve the transparency of staff selection procedures; acknowledges that Selection Board members did not always complete their conflict of interest declarations or did not do so in a timely manner, and there was no evidence of any action taken to address the issues raised by these declarations; acknowledges that the documentation of the Selection Board’s proceedings was not always adequate and that there is no evidence as to how the method for the short-listing of candidates was established and that the questions for the written tests or interviews were set before the examinations, and therefore urges the Agency, in common with other agencies and authorities, to appoint an ethics adviser for these procedures;
Amendment 16 #
Motion for a resolution Paragraph 10 10. Notes from the Agency that it has taken note of the Court of Auditors' comments
Amendment 17 #
Motion for a resolution Paragraph 11 a (new) 11a. Notes that according to the findings of the Court of Auditors, at the time of completion of the field work (October 2011), the Agency did not adequately manage conflict of interest situations but has developed one of the most advanced policies and procedure for declaring, assessing and managing conflicts of interest;
Amendment 18 #
Motion for a resolution Paragraph 11 a (new) 11a. Notes with concern that according to the findings of the Court of Auditors, at the time of completion of the field work (October 2011), the Authority did not adequately manage conflict of interest situations; notes, however, that the Authority had already developed advanced policies for managing conflicts of interest;
Amendment 19 #
Motion for a resolution Paragraph 12 – introductory part 12.
Amendment 2 #
Proposal for a decision 1 Paragraph 1 1.
Amendment 20 #
Motion for a resolution Paragraph 12 – introductory part 12. Notes that the Agency has taken a number of steps following the discharge authority's recommendations for 2010, the Court of Auditors' audit and the publication of Special Report 15/2012, in particular:
Amendment 21 #
Motion for a resolution Paragraph 12 a (new) 12a. Welcomes the Agency's commitment to undertake in the first half of 2013 a review of the implementation of its revised policy on the handling of conflicts of interests and that an ex ante and ex post check on the handling of conflicts of interests is currently being developed for implementation in the second quarter of 2013; calls on the Agency to keep the discharge authority informed on their respective outcomes;
Amendment 22 #
Motion for a resolution Paragraph 12 b (new) 12b. Welcomes that after the former Head of Legal Service left the Agency to join as senior counsel a US-based law firm having a number of pharmaceutical industry companies as clients in June 2012 the Executive Director of the Agency launched a review of his work as Head of the Legal Service, Chair of the Joint Committee, Chair of the Disciplinary Committee and member of the Advisory Committee on Procurement and Contracts; acknowledges that no evidence of conflicts of interest nor breach of obligations provided in Articles 11 and 11a of the Staff Regulations could be identified ; welcomes that in accordance with Article 16 of the Staff Regulations the Executive Director imposed some restrictions to the activities of the former Head of Legal Service for a period of two years following his leaving the EMA; calls on the Agency to provide the discharge authority with detailed information on those restrictions;
Amendment 23 #
Motion for a resolution Paragraph 12 – subparagraph 1 urges the Agency to report to the discharge authority on a 6 months basis on the implementation of the abovementioned policies and procedures, as well as on any further developments as regards management of conflict of interest;
Amendment 24 #
Motion for a resolution Paragraph 12 – subparagraph 1 urges the Agency to continue implementing the Court of Auditors' recommendations in order to avoid any conflict of interest in its various structures of governance and operation, and to report to the discharge authority on the implementation of the abovementioned policies and procedures, as well as on any further developments as regards management of conflict of interest;
Amendment 25 #
Motion for a resolution Paragraph 12 – subparagraph 1 a (new) Calls on the agency to start a structured dialogue with civil society on matters relating to conflicts of interest and to invite those organisations concerned at least twice a year to discuss matters of common interest based on a agreed agenda and to inform the discharge authorities on the outcome of these deliberations;
Amendment 3 #
Proposal for a decision 1 Paragraph 1 1.
Amendment 4 #
Proposal for a decision 2 Paragraph 1 1.
Amendment 5 #
Proposal for a decision 2 Paragraph 1 1.
Amendment 6 #
Proposal for a decision 2 Paragraph 1 1.
Amendment 7 #
Motion for a resolution Recital D D. whereas the overall contribution of the Union to the Agency's budget for 2011 was EUR 39 765 191,39
Amendment 9 #
Motion for a resolution Paragraph 1 1.
source: PE-497.879
|
History
(these mark the time of scraping, not the official date of the change)
| docs/0 |
|
| events/0/date |
Old
2012-07-25T00:00:00New
2012-07-24T00:00:00 |
| events/4/docs |
|
| committees/0/shadows/4 |
|
| docs/1/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE497.831New
https://www.europarl.europa.eu/doceo/document/CONT-PR-497831_EN.html |
| docs/2/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE500.745&secondRef=02New
https://www.europarl.europa.eu/doceo/document/ENVI-AD-500745_EN.html |
| docs/4/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE497.879New
https://www.europarl.europa.eu/doceo/document/CONT-AM-497879_EN.html |
| events/0/docs/0/url |
Old
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdfNew
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdf |
| events/1/type |
Old
Committee referral announced in Parliament, 1st reading/single readingNew
Committee referral announced in Parliament |
| events/2/type |
Old
Vote in committee, 1st reading/single readingNew
Vote in committee |
| events/3 |
|
| events/3 |
|
| events/4/docs |
|
| events/6 |
|
| events/6 |
|
| committees/0 |
|
| committees/0 |
|
| committees/1 |
|
| committees/1 |
|
| events/0/docs/0/url |
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdfNew
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdf |
| events/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-98&language=ENNew
http://www.europarl.europa.eu/doceo/document/A-7-2013-0098_EN.html |
| events/5 |
|
| events/5 |
|
| events/6 |
|
| events/6/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2013-150New
http://www.europarl.europa.eu/doceo/document/TA-7-2013-0150_EN.html |
| activities |
|
| commission |
|
| committees/0 |
|
| committees/0 |
|
| committees/1 |
|
| committees/1 |
|
| docs |
|
| events |
|
| links |
|
| other |
|
| procedure/dossier_of_the_committee |
Old
CONT/7/10520New
|
| procedure/final/url |
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32013D0584New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32013D0584 |
| procedure/subject |
Old
New
|
| activities/0/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/0/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/0/docs/0/url |
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdfNew
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdf |
| activities/0/type |
Old
Non-legislative basic documentNew
Non-legislative basic document published |
| activities/1 |
|
| activities/1/committees |
|
| activities/1/date |
Old
2013-01-23T00:00:00New
2012-09-13T00:00:00 |
| activities/1/docs |
|
| activities/1/type |
Old
Committee draft reportNew
Committee referral announced in Parliament, 1st reading/single reading |
| activities/2/body |
EP
|
| activities/2/committees |
|
| activities/2/date |
Old
2013-11-16T00:00:00New
2013-03-19T00:00:00 |
| activities/2/type |
Old
Final act published in Official JournalNew
Vote in committee, 1st reading/single reading |
| activities/4 |
|
| activities/5 |
|
| activities/5/type |
Old
Text adopted by Parliament, single readingNew
Decision by Parliament, 1st reading/single reading |
| activities/6 |
|
| activities/6/body |
EP
|
| activities/6/committees |
|
| activities/6/date |
Old
2012-09-13T00:00:00New
2013-11-16T00:00:00 |
| activities/6/docs |
|
| activities/6/text |
|
| activities/6/type |
Old
Committee referral announced in Parliament, 1st reading/single readingNew
Final act published in Official Journal |
| committees/0/committee |
Old
ENVINew
CONT |
| committees/0/committee_full |
Old
Environment, Public Health and Food SafetyNew
Budgetary Control |
| committees/0/date |
Old
2012-09-20T00:00:00New
2012-02-29T00:00:00 |
| committees/0/rapporteur/0/group |
Old
S&DNew
ALDE |
| committees/0/rapporteur/0/mepref |
Old
4de185430fb8127435bdbebdNew
4f1ac83bb819f25efd0000d5 |
| committees/0/rapporteur/0/name |
Old
HAUG JuttaNew
GERBRANDY Gerben-Jan |
| committees/0/responsible |
Old
New
True |
| committees/0/shadows |
|
| committees/1/committee |
Old
CONTNew
ENVI |
| committees/1/committee_full |
Old
Budgetary ControlNew
Environment, Public Health and Food Safety |
| committees/1/date |
Old
2012-02-29T00:00:00New
2012-09-20T00:00:00 |
| committees/1/rapporteur/0/group |
Old
ALDENew
S&D |
| committees/1/rapporteur/0/mepref |
Old
4de185240fb8127435bdbe92New
4f1ac8f6b819f25efd000102 |
| committees/1/rapporteur/0/name |
Old
GERBRANDY Gerben-JanNew
HAUG Jutta |
| committees/1/responsible |
Old
TrueNew
|
| committees/1/shadows |
|
| procedure/final |
|
| activities/10 |
|
| procedure/stage_reached |
Old
Procedure completed, awaiting publication in Official JournalNew
Procedure completed |
| activities/0/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/0/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/8/docs |
|
| activities/8/docs |
|
| procedure/Modified legal basis |
$procedure.legalBasisListProposed
|
| procedure/legal_basis |
|
| activities/8/docs |
|
| procedure/?!oeil-proposed_legal_basis!? |
$procedure.legalBasisListProposed
|
| procedure/Modified legal basis |
$procedure.legalBasisListProposed
|
| activities/8/docs |
|
| procedure/?!oeil-proposed_legal_basis!? |
$procedure.legalBasisListProposed
|
| procedure/legal_basis |
|
| activities/8/docs |
|
| activities/9/docs/0/text/0 |
Old
The European Parliament adopted a decision on discharge to be granted to the Executive Director of the European Medicines Agency (EMA) in respect of the implementation of the Agency's budget for the financial year 2011. The vote on the decision to grant discharge covers the closure of the accounts (in accordance with Annex VI, Rule 5(1) of the European Parliament’s Rules of Procedure). Noting that the Court of Auditors stated that it has obtained reasonable assurances that the annual accounts of the Agency for the financial year 2011 are reliable and that the underlying transactions are legal and regular, Parliament adopted a resolution containing a number of recommendations that need to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies:
Lastly, Parliament made a series of observations concerning the procurement procedures and controls carried out by this Community Agency. New
The European Parliament adopted a decision on discharge to be granted to the Executive Director of the European Medicines Agency (EMA) in respect of the implementation of the Agency's budget for the financial year 2011. The vote on the decision to grant discharge covers the closure of the accounts (in accordance with Annex VI, Article 5(1) of the European Parliament’s Rules of Procedure). Noting that the Court of Auditors stated that it has obtained reasonable assurances that the annual accounts of the Agency for the financial year 2011 are reliable and that the underlying transactions are legal and regular, Parliament adopted a resolution containing a number of recommendations that need to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies:
Lastly, Parliament made a series of observations concerning the procurement procedures and controls carried out by this Community Agency. |
| activities/9/docs/0/text |
|
| activities/8/type |
Old
Indicative plenary sitting date, 1st reading/single readingNew
Debate in Parliament |
| activities/9/docs |
|
| activities/9/type |
Old
Vote in plenary scheduledNew
Text adopted by Parliament, single reading |
| procedure/stage_reached |
Old
Awaiting Parliament 1st reading / single reading / budget 1st stageNew
Procedure completed, awaiting publication in Official Journal |
| activities/7/docs/0/text |
|
| activities/7/docs/0/url |
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-98&language=EN
|
| activities/7 |
|
| activities/6 |
|
| activities/7 |
|
| activities/5/docs/0/url |
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE497.879
|
| activities/4/docs/0/text |
|
| activities/0/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/5 |
|
| activities/0/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/1/docs/1/text |
|
| activities/0/docs/0/text/0 |
Old
PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2011, as part of the 2011 discharge procedure. Analysis of the accounts of the European Medicines Agency (EMEA). CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2011 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA). In 2011, the tasks and budget of this agency were as follows:
The complete version of the Agency's final accounts may be found at the following address: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500129887.pdf New
PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2011, as part of the 2011 discharge procedure. Analysis of the accounts of the European Medicines Agency (EMEA). CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2011 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA). In 2011, the tasks and budget of this agency were as follows:
The complete version of the Agency's final accounts may be found at the following address: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500129887.pdf |
| activities/4/docs/0/url |
http://register.consilium.europa.eu/servlet/driver?page=Result&lang=EN&typ=Advanced&cmsid=639&ff_COTE_DOCUMENT=5753%2F13&fc=REGAISEN&srm=25&md=100
|
| activities/2/committees/0/shadows/0 |
|
| activities/4 |
|
| committees/0/shadows/0 |
|
| activities/3/docs/0/url |
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE497.831
|
| activities/1 |
|
| activities/2 |
|
| activities/0 |
|
| activities/0/body |
Old
EPNew
EC |
| activities/0/commission |
|
| activities/0/date |
Old
2013-05-09T00:00:00New
2012-07-25T00:00:00 |
| activities/0/docs |
|
| activities/0/type |
Old
EP 1R PlenaryNew
Non-legislative basic document |
| activities/1 |
|
| activities/3 |
|
| activities/4 |
|
| activities/7 |
|
| activities/2/committees/0/shadows/0 |
|
| committees/0/shadows/0 |
|
| activities/1/docs/0/url |
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2012&nu_doc=436New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2012/0436/COM_COM(2012)0436_EN.pdf |
| activities/5 |
|
| activities/6/type |
Old
Indicative plenary sitting date, 1st reading/single readingNew
EP 1R Plenary |
| activities/7 |
|
| activities/1/docs/0/celexid |
CELEX:52012DC0436:EN
|
| activities/1/docs/0/text |
|
| activities/2/committees/0/shadows/0 |
|
| activities/2/committees/0/shadows/2/mepref |
Old
4de185660fb8127435bdbeeeNew
4de182da0fb8127435bdbb40 |
| activities/2/committees/0/shadows/2/name |
Old
HERCZOG EditNew
AYALA SENDER Inés |
| committees/0/shadows/0 |
|
| committees/0/shadows/2/mepref |
Old
4de185660fb8127435bdbeeeNew
4de182da0fb8127435bdbb40 |
| committees/0/shadows/2/name |
Old
HERCZOG EditNew
AYALA SENDER Inés |
| activities/4 |
|
| activities/3 |
|
| activities/2/committees/0/date |
2012-02-29T00:00:00
|
| activities/2/committees/0/rapporteur |
|
| activities/2/committees/0/shadows |
|
| committees/0/date |
2012-02-29T00:00:00
|
| committees/0/rapporteur |
|
| committees/0/shadows |
|
| activities |
|
| committees |
|
| links |
|
| other |
|
| procedure |
|